0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > KRAS

KRAS

Brief Information

Name:V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Target Synonym:KRAS,V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
KRS-H51H4 Human Human KRAS (2-185,G12D) Protein, His Tag
KRS-H51H4-structure
KRS-H51H3 Human Human KRAS (2-185,G12C) Protein, His Tag
KRS-H51H3-structure
KRS-H5547 Human Human KRAS Protein, His Tag
KRS-H5547-structure
KRS-H5547-sds

Synonym Name

GTPase Kras,K-Ras 2,Ki-Ras,c-K-ras,c-Ki-ras,KRAS2,RASK2,C-K-RAS,CFC2,K-RAS2A,K-RAS2B,K-RAS4A,K-RAS4B,KI-RAS,KRAS1,KRAS2,NS,NS3,RASK2,KRAS

Background

KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) gene is a proto-oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is also known as Ki-Ras, c-K-ras andc-Ki-ras. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. RAS is one of the most frequently mutated oncogenes in human cancer but the frequency and distribution of RAS gene mutations are not uniform. In details, mutation of glycine 12 (G12) causes RAS activation by interfering with GAP binding and GAP-stimulated GTP hydrolysis. The reference shows the pathway may as a potential therapy targets.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sotorasib AMG-510 Approved Amgen Inc LUMAKRAS United States Carcinoma, Non-Small-Cell Lung Amgen Inc 2021-05-28 Solid tumours; Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Autologous anti-KRAS G12V mTCR gene-engineered cell therapy (National Cancer Institute) Phase 2 Clinical National Cancer Institute Gastrointestinal Neoplasms Details
CWG-71a (Cellworks Group) CWG-71a Clinical Cellworks Neoplasms Details
Antroquinonol Phase 2 Clinical Golden Biotechnology Corporation Ltd Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Hepatitis B; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Hyperlipidemias; Dermatitis, Atopic Details
JNJ-74699157 ARS-3248; JNJ-74699157 Phase 1 Clinical Janssen Global Services Llc Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
JAB-3312 JAB-3312 Phase 2 Clinical Jacobio Pharmaceuticals Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
GDC-6036 Phase 1 Clinical Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
D-1553 D-1553 Phase 2 Clinical Inventisbio Inc Solid tumours; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung Details
BI-1701963 BI-1701963 Phase 1 Clinical Forma Therapeutics Solid tumours; Colorectal Neoplasms Details
KRASG12D-LODER KRASG12D-LODER; siG12D-LODER Phase 2 Clinical Silenseed Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal Details
JDQ-443 JDQ-443; JDQ443 Phase 2 Clinical Novartis Pharmaceuticals Corp Solid tumours; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Adagrasib MRTX-849 Phase 3 Clinical Mirati Therapeutics Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
BPI-421286 BPI-421286 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
GF-105 GF-105; GFH-925 Phase 2 Clinical Genfleet Therapeutics (Shanghai) Inc Solid tumours; Carcinoma, Non-Small-Cell Lung Details
JAB-21822 JAB-21822; JAB21822 Phase 2 Clinical Jacobio Pharmaceuticals Co Ltd Solid tumours; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
LY-3537982 LY-3537982 Phase 1 Clinical Eli Lilly And Company Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
GH-35 GH-35 Phase 1 Clinical Suzhou GenHouse pharmaceutical Co Ltd Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop